“I am so happy that I made the right decision by choosing your firm without any second thoughts. All my questions were answered promptly, also I am highly satisfied with the level of assistance and the attorney’s meticulous way of preparing my NIW petition is commendable. Appreciate your team’s patience all along the way and the revision of petition letters multiple times to my (client’s) satisfaction is one of the highlights of the service I had experienced with your firm. The way the lawyer prepared the RFE Response and highlighted the evidence and steps involved in the RFE resolution is very clear and to the point. Really appreciate my attorney’s patience throughout the process of resolving my NIW RFE. I am happy that I got to work with such an amazing person. HIGHLY RECOMMENDED!!!!”

Case Summary:

A senior drug safety specialist from India in the field of biomedical sciences reached out to North America Immigration Law Group back in June 2022 to get her profile evaluated for an NIW (National Interest Waiver) visa. Since we have a track record of more than 32,000 approved visa cases, we evaluated her credentials thoroughly, and we were confident enough to get her the desired approval.

Our diligent team of North America Immigration Law Group is highly strategic in establishing our client’s need to determine a strong case for a National Interest Waiver (NIW). Our approach hinges on presenting only the most relevant and compelling evidence with each petition while still ensuring that our client’s unique achievements and abilities are effectively showcased.

Therefore, when our client with an M.Pharm. degree approached us by presenting her proposed endeavor focusing on the pre-clinical toxicity studies of novel small molecules and safety monitoring of pharmaceutical therapies for alcohol and opioid dependence, schizophrenia and bipolar disorder, cancers, and neurodegenerative disorders, we were certain that USCIS would agree to the fact that by developing viable new drug treatments against cancers and other diseases, our client is serving the healthcare interests of the United States. Thus, her work is indisputably valuable to the fight against cancer and neurodegeneration, as well as the public health interests of the United States as a whole.

Despite preparing an emphasizing petition packet, she received an RFE (request for evidence). Receiving an RFE was discouraging for both our team and our client, causing our client to question if her case was indeed strong enough for approval. However, our esteemed attorneys and team members reassured her that we would be able to submit an RFE response explaining in detail the evidence that was required to further reinforce our arguments. The petition was ultimately approved, underscoring that while every case is unique so is our commitment to the individual needs of every one of our clients is a perpetual.

Our happy client successfully secured her NIW approval just 6 months after the RFE response submission, and she retained us for the EB1A (Alien of Extraordinary Ability) petition. Though the EB1A visa category is slightly different than the NIW petition, we geared up to help her to the best of our abilities.

To prepare a persuasive case in her favor, we included the following details in her petition packet:

• Her work has resulted in 17 peer-reviewed scientific articles.
• Her strong contributions, as indicated by her records of citation i.e. 231 citations received from several experts in the field from at least 38 countries as well as the valuable applications of her work in reducing preclinical trial costs, establish her as a true leader in her field.
• In addition to the significant research she is producing, our client serves the biomedical sciences community as a peer review moderator. She has conducted 25 reviews to date. This is reserved solely for the most knowledgeable researchers, and her repeated invitations to conduct peer reviews are indicative of her impressive status in the field.

We concluded that the preexisting, independent, and objective evidence that her original contributions are of major significance. This is supported by contextual statements from other experts in her field. One of them stated the below mentioned:

“[Client’s] method significantly reduces preclinical trial costs, ultimately helping to reduce drug costs for consumers. Considering the high cost of prescription drugs in the United States, her work is of significant value to the country.”

Lastly, after submitting all the objective evidence, which includes evidence of her significant governmental funding, her publication and citation record, and her overall record of success and significant influence in the field, demonstrating that her findings are indeed original and represent unique and substantive contributions to the academic field of research. Based on this extraordinary record, she also obtained her EB1A approval.

Once again, the premium processing service has proved to be a great support to our client’s case as her EB1A case got approval by USCIS just 10 days after the upgrade, without any RFE. It was a great experience working with our client, and we truly appreciate her for her throughout support with us. Also, we thank her for trusting our law firm and allowing us to be a part of this wonderful story.